A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes

Trial Profile

A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Insulin glargine/insulin lispro (Primary) ; Insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Adocia
  • Most Recent Events

    • 25 Jan 2018 Primary endpoint has been met. (Cmax_total), as reported in an Adocia media release.
    • 25 Jan 2018 Primary endpoint has been met. (AUC last_total), as reported in an Adocia media release.
    • 25 Jan 2018 Results published in an Adocia Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top